The above-mentioned indicated that FAK/RAS mutation might be responsible for the extramedullary spread and great clinical efficacy can be achieved in MM with EMD by targeting FAK and/or RAS signaling pathways. The gene discussed is PTK2; the disease is Miyoshi myopathy.